Acumen Pharmaceuticals, Inc. (ABOS) Debt Components
- 2026-06-30: Short-term DebtUSD $19.67M; Long-term DebtUSD $11.90M; Debt, Long-term and Short-term, Combined AmountUSD $31.57M.
- 2026-03-31: Short-term DebtUSD $14.12M; Long-term DebtUSD $16.92M; Debt, Long-term and Short-term, Combined AmountUSD $31.05M.
- 2025-12-31: Short-term DebtUSD $8.77M; Long-term DebtUSD $22.40M; Debt, Long-term and Short-term, Combined AmountUSD $31.16M.
- 2025-09-30: Short-term DebtUSD $3.60M; Long-term DebtUSD $27.05M; Debt, Long-term and Short-term, Combined AmountUSD $30.65M.
Acumen Pharmaceuticals, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Short-term Debt USD | Long-term Debt USD | Debt, Long-term and Short-term, Combined Amount USD |
|---|---|---|---|
| 2026-06-30 | $19.67M | $11.90M | $31.57M |
| 2026-03-31 | $14.12M | $16.92M | $31.05M |
| 2025-12-31 | $8.77M | $22.40M | $31.16M |
| 2025-09-30 | $3.60M | $27.05M | $30.65M |
| 2025-06-30 | (m) | $29.88M | (m) |
| 2025-03-31 | (m) | $29.53M | (m) |
| 2024-12-31 | $0.00 | $29.42M | $29.42M |
| 2024-09-30 | (m) | $29.67M | (m) |
| 2024-06-30 | (m) | $29.38M | (m) |
| 2024-03-31 | (m) | $30.21M | (m) |
| 2023-12-31 | (m) | $29.90M | (m) |
| 2022-12-31 | (m) | $0.00 | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |